POSTER PRESENTATION

Open Access

Inhibition of receptor for advanced glycation end-products (RAGE) improves alveolar fluid clearance and lung injury in a mouse model of acute respiratory distress syndrome (ARDS)

R Blondonnet^{1,2*}, J Audard^{1,2}, G Clairefond², C Belville², D Bouvier^{2,3}, L Blanchon², V Sapin^{2,3}, JM Constantin^{1,2}, M Jabaudon^{1,2}

From ESICM LIVES 2015 Berlin, Germany. 3-7 October 2015

Rationale

The receptor for advanced glycation end-products (RAGE) is a transmembrane multipattern receptor abundantly expressed on the basal surface of alveolar type (AT) I cells. RAGE is implicated in ARDS-associated alveolar inflammation [1,2], but its precise roles in lung injury remain unknown. It has been shown recently that RAGE axis could impact alveolar fluid clearance (AFC) through the modulation of epithelial sodium channels [3]. In mouse models of sepsis and of ARDS, treatment with anti-RAGE monoclonal antibody decreased mortality, and treatment with recombinant soluble RAGE (sRAGE, acting as a decoy receptor) was associated with improved lung injury.

Objective


Using a murine model of ARDS, we evaluated whether RAGE modulation could regulate lung injury and AFC.

Methods

60 anesthetised male C57BL/6JTj mice were divided in 4 groups; 3 of them underwent orotracheal installation of hydrochloric acid (day 0). Among these acid-injured mice, some were intravenously treated with an anti-RAGE monoclonal antibody (mAb) or intraperitoneal recombinant soluble RAGE (sRAGE). Mice from the Sham group underwent orotracheal instillation of saline and served as controls. At specified time-points (day 0,

¹CHU Clermont-Ferrand, Department of Anaesthesiology and Intensive Care Medicine, Clermont-Ferrand, France

Full list of author information is available at the end of the article



Results

Acid-injured mice had higher permeability indexes, higher BAL IL-6 and marked hypoxemia on day 1 and 2, as compared with sham animals. AFC rates and PaO2/FiO2 ratios were higher in controls (35%/30min and 281 [262-319], respectively) than in HCl-injured mice on day 1 (8% and 181 [176-198], respectively, P < 0.0001) and day 2 (9% and 186 [174-205], respectively, P < 0.0001).


RAGE inhibition restored AFC on day 1 in both mAbtreated (8% versus 36%, p = 0.009) and sRAGE-treated (8% versus 37% p = 0,009) mice. RAGE inhibition significantly improved both PaO2/FiO2 ratio and permeability index on day 1, day 2, and anti-RAGE therapy could prevent increased BAL IL-6 levels on day 1 an day 2 in HCl-treated mice.

Discussion

Our results support the efficacy of a RAGE inhibition strategy in improving AFC and lung injury in a translational mouse model of ARDS, and RAGE pathway may represent a therapeutic target during ARDS. Such findings should stimulate further research on the mechanistic links between RAGE pathway, AFC and lung alveolar injury and its resolution.



© 2015 Blondonnet et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Authors' details

¹CHU Clermont-Ferrand, Department of Anaesthesiology and Intensive Care Medicine, Clermont-Ferrand, France. ²Auvergne University, R2D2 - EA7281, Clermont-Ferrand, France. ³CHU Clermont-Ferrand, Department of Medical Biochemistry and Molecular Biology, Clermont-Ferrand, France.

Published: 1 October 2015

References

- 1. Genes Cells 2004, 9(2):165-74.
- 2. Crit Care Med 2011, 39(3):480-488.
- 3. Am J Respir Cell Mol Biol 2015, 52(1):75-87, Jan.

doi:10.1186/2197-425X-3-S1-A804

Cite this article as: Blondonnet *et al.*: **Inhibition of receptor for** advanced glycation end-products (RAGE) improves alveolar fluid clearance and lung injury in a mouse model of acute respiratory distress syndrome (ARDS). *Intensive Care Medicine Experimental* 2015 **3**(Suppl 1):A804.

Submit your manuscript to a SpringerOpen[™] journal and benefit from:

- ► Convenient online submission
- ► Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- ► High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com